Welcome to our dedicated page for Protalix Biother news (Ticker: PLX), a resource for investors and traders seeking the latest updates and insights on Protalix Biother stock.
Protalix BioTherapeutics (NYSE: PLX) is a biopharmaceutical innovator leveraging its proprietary ProCellEx® plant cell-based technology to develop enzyme replacement therapies for rare diseases. This page provides investors and industry stakeholders with timely updates on clinical developments, regulatory milestones, and strategic partnerships.
Access comprehensive coverage of PLX's advancements in treating Gaucher disease, Fabry disease, and other rare conditions. Track updates across three key areas: clinical trial progress for pipeline candidates, commercial partnerships with global pharmaceutical leaders, and manufacturing innovations through the ProCellEx® platform.
Our curated news collection enables efficient monitoring of FDA submissions, earnings reports, and licensing agreements. Stay informed about the company's unique approach to cost-effective bioproduction and its expanding role in addressing unmet medical needs through plant-based protein expression systems.
Bookmark this page for direct access to verified press releases and objective analysis of Protalix's position within the competitive rare disease therapeutics market. Regular updates ensure you maintain current awareness of developments impacting both clinical outcomes and investment considerations.
Protalix BioTherapeutics, Inc. (NYSE American: PLX) announced its Q2 2022 financial results and business updates on August 15, 2022. The firm reported revenues of $3.4 million from goods, a 6% increase year-over-year, and $5.4 million from licenses and R&D services, a 69% increase. The cost of goods sold decreased by 13% to $4.1 million. Research expenses slightly fell by 1% to $7.6 million, while SG&A expenses dropped by 19% to $2.6 million. The net loss narrowed to approximately $5.3 million, down from $11.2 million in Q2 2021. Protalix confirmed positive results from the phase III BALANCE trial for PRX-102.
Protalix BioTherapeutics (NYSE American: PLX) will announce its second-quarter 2022 financial results and provide a business update on August 15, 2022. A conference call with investors is scheduled for the same day at 8:30 a.m. EDT, where management will discuss financial results and recent corporate updates. Protalix is known for its ProCellEx protein expression system and has FDA-approved products, including taliglucerase alfa. The company has a strong pipeline targeting various medical conditions.
Protalix BioTherapeutics (NYSE American: PLX) has appointed Shmuel 'Muli' Ben Zvi, Ph.D., to its Board of Directors. Dr. Ben Zvi, who brings extensive financial and management expertise, will also serve on the Audit and Compensation Committees. His prior experience includes senior roles at Teva Pharmaceuticals and positions on various boards including Bank Leumi. Protalix is known for its innovative plant cell-based expression system and has FDA-approved products, ensuring its commitment to developing recombinant therapeutic proteins.
Protalix BioTherapeutics (NYSE:PLX) announced five poster presentations to be featured at the 2022 Program: 7th Update on Fabry Disease, highlighting crucial clinical trial results. Scheduled from May 29-31, 2022, in Würzburg, Germany, presentations include data on the safety and efficacy of Pegunigalsidase Alfa for Fabry disease. Notable studies include 24-month results from the Phase III BALANCE study and long-term data from various trials. The presentations will be available on Protalix's website, showcasing its commitment to advancing treatment options in this therapeutic area.
Protalix BioTherapeutics (PLX) reported Q1 2022 financial results, showing a 100% revenue increase to $9.0 million compared to Q1 2021. The company advanced its Fabry disease treatment, PRX-102, completing three phase III trials and preparing for a BLA resubmission to the FDA. Key studies, BRIGHT and BALANCE, demonstrated significant efficacy and safety. R&D expenses rose by 24% to $8.8 million, while net loss improved to $2.3 million. The company holds $32.9 million in cash as of March 31, 2022. A conference call is scheduled for today at 8:30 a.m. EDT.
Protalix BioTherapeutics (NYSE: PLX) will release its first-quarter 2022 financial results on May 16, 2022, and host a conference call at 8:30 a.m. EDT. The call will address financials and provide updates on corporate and clinical developments. The company specializes in recombinant therapeutic proteins using its ProCellEx plant cell-based expression system, with FDA-approved products like taliglucerase alfa. Protalix is also developing several candidates targeting various diseases, including Fabry disease and respiratory conditions.
Protalix BioTherapeutics (PLX) and Chiesi Global Rare Diseases announced positive topline results from the BALANCE pivotal Phase III trial for PRX–102, a novel enzyme replacement therapy for Fabry disease. The trial, involving 78 adult patients, demonstrated non-inferiority of PRX–102 compared to agalsidase beta in slowing kidney function decline, a key outcome measure. The median eGFR slope in the PRX–102 group was -2.514 mL/min/1.73 m²/year, while the agalsidase beta group had -2.155 mL/min/1.73 m²/year. The favorable safety profile and positive results strengthen the case for regulatory submission for PRX–102's approval.
Protalix BioTherapeutics, Inc. (NYSE American: PLX) reported its fiscal year 2021 financial results, highlighting a revenue of $16.7 million, a 3% increase from 2020. However, revenues from licenses and R&D services fell by 54%, totaling $21.6 million. The net loss for 2021 was approximately $27.6 million, or $0.62 per share, compared to a loss of $6.5 million in 2020. Notable developments include a validated Marketing Authorization Application to the EMA for PRX-102 for Fabry disease and positive preliminary results from its phase III BRIGHT clinical trial.
Protalix BioTherapeutics, Inc. (NYSE American: PLX) will announce its fiscal year 2021 financial results and provide a business update on March 31, 2022, at 8:30 a.m. EDT. The conference call will cover recent corporate and clinical developments. Protalix, known for its ProCellEx® plant cell-based protein expression system, aims to enhance its pipeline, which includes therapies for Fabry disease and other conditions. Investors can join the call via phone or webcast, with links provided for access.
Protalix BioTherapeutics (NYSE: PLX) and Chiesi Global Rare Diseases announced final results from the BRIGHT Phase III trial for PRX-102, aimed at treating Fabry disease. The trial showed that PRX-102 at 2 mg/kg every four weeks was well tolerated, with stable eGFR and lyso-Gb3 levels. Out of 30 enrolled patients, 29 completed the study, showcasing a favorable safety profile with no severe treatment-related adverse events. The companies plan to seek regulatory approvals for PRX-102, which could provide a new treatment option for Fabry patients currently on enzyme replacement therapy.
FAQ
What is the current stock price of Protalix Biother (PLX)?
What is the market cap of Protalix Biother (PLX)?
